81 related articles for article (PubMed ID: 23030220)
1. Comment on 'The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer'.
Kitchen D; O'Brien M; Hughes B; Gill I; Rumbles S; Ellis P; Stebbing J
Br J Cancer; 2013 Jul; 109(2):526-8. PubMed ID: 23756861
[No Abstract] [Full Text] [Related]
2. Adjuvant trastuzumab: does time really matter?
Swain SM
Oncologist; 2013; 18(5):490-2. PubMed ID: 23624497
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of squamous cell carcinoma of the anal canal.
Armstrong SA; Malley R; Wang H; Lenz HJ; Arguello D; El-Deiry WS; Xiu J; Gatalica Z; Hwang JJ; Philip PA; Shields AF; Marshall JL; Salem ME; Weinberg BA
J Gastrointest Oncol; 2021 Oct; 12(5):2423-2437. PubMed ID: 34790403
[TBL] [Abstract][Full Text] [Related]
4. Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.
Murphy C; Muscat A; Ashley D; Mukaro V; West L; Liao Y; Chisanga D; Shi W; Collins I; Baron-Hay S; Patil S; Lindeman G; Khasraw M
PLoS One; 2019; 14(2):e0210891. PubMed ID: 30763338
[TBL] [Abstract][Full Text] [Related]
5. The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.
Diver EJ; Foster R; Rueda BR; Growdon WB
Oncologist; 2015 Sep; 20(9):1058-68. PubMed ID: 26099744
[TBL] [Abstract][Full Text] [Related]
6. Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer.
Ghochikyan A; Pichugin A; Bagaev A; Davtyan A; Hovakimyan A; Tukhvatulin A; Davtyan H; Shcheblyakov D; Logunov D; Chulkina M; Savilova A; Trofimov D; Nelson EL; Agadjanyan MG; Ataullakhanov RI
J Transl Med; 2014 Nov; 12():322. PubMed ID: 25432242
[TBL] [Abstract][Full Text] [Related]
7. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
Groeneweg JW; Hernandez SF; Byron VF; DiGloria CM; Lopez H; Scialabba V; Kim M; Zhang L; Borger DR; Tambouret R; Foster R; Rueda BR; Growdon WB
Clin Cancer Res; 2014 Dec; 20(24):6517-6528. PubMed ID: 25294905
[TBL] [Abstract][Full Text] [Related]
8. Breast tumor and stromal cell responses to TGF-β and hypoxia in matrix deposition.
Curran CS; Keely PJ
Matrix Biol; 2013 Mar; 32(2):95-105. PubMed ID: 23262216
[TBL] [Abstract][Full Text] [Related]
9. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
10. Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Khasraw M; Bell R
Expert Rev Anticancer Ther; 2012 Aug; 12(8):1005-13. PubMed ID: 23030220
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
Coudert BP; Largillier R; Arnould L; Chollet P; Campone M; Coeffic D; Priou F; Gligorov J; Martin X; Trillet-Lenoir V; Weber B; Bleuse JP; Vasseur B; Serin D; Namer M
J Clin Oncol; 2007 Jul; 25(19):2678-84. PubMed ID: 17515572
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
[TBL] [Abstract][Full Text] [Related]
13. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
14. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
